Middle East tapentadol Market Increases Steadily in Emerging Countries by 2026: Depomed, Inc., Janssen Pharmaceutical, Inc., Grünenthal, and Allergan Plc

Janssen Pharmaceutical sold its license of marketing and distribution of the U.S. to Depomed, Inc. and in April 2017, Depomed, Inc. won the patent for tapentadol. Three ongoing clinical trials for tapentadol are being carried on for various indications and age groups. Positive results from these trials is expected to cause the tapentadol market to gain rapid traction. Currently, tapentadol is only approved for consumption by adults and is not recommended for children due to its high therapeutic efficacy. However, one in three clinical trials are subjected to pediatric use. Grünenthal GmbH is carrying out an open-label trial, enrolling subjects aged 6 years to 18 years, which is estimated to be completed in December 2018. Another trial by St. Olavs Hospital is for pre- and post-operative pain relief after primary knee arthroplasty with estimated study completion year 2021.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/1054

Tapentadol can be used for various other applications, as it is also found to be the safest and best first-line treatment choice for advanced chronic kidney disease. However, clinical trials are still required for it to be prescribed for the same. Furthermore, pilot studies have been performed on patients suffering from moderate-to-severe chronic back pain, published in the National Center for Biotechnology Information.

Increasing off-label applications for this moderately addictive drug along with low competition for existing indications, and robust pipeline is expected to boost growth of the tapentadol market over the forecast period.

The Middle East tapentadol market is expected to gain significant traction, provided that the product distribution is restructured by the patent holder, globally. Support from the regulatory bodies in the Middle East, and increase in accessibility of tapentadol is expected to support growth of Middle East tapentadol market. Absence of major distribution channel for tapentadol in the Middle East has drastically reduced the import options.

This provides immense opportunities for local players such as Teva Pharmaceutical Industries Ltd. to set up a distribution channel with the drug patent holder. Tapentadol is the only U.S. Food & Drug Administration approved opioid drug for treatment of diabetic neuropathic pain. Currently, only adults can consume tapentadol due to high therapeutic efficacy, which is not recommended for children. Whereas, ongoing clinical trials are expected to culminate in tapentadol being subjected to pediatric use, positive result of which, are expected to fuel growth of the Middle East tapentadol market over the forecast period.

Get Request Sample Copy of Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1054

Detailed Segmentation:

Middle East Tapentadol Market, By Therapeutic Application:
Pain Management
Neuropathic Pain
Cancer Pain
Others
Cough Treatment
Middle East Tapentadol Market, By Countries:
KSA
Country Trends and Estimation (US$ Million)*
UAE
Bahrain
Oman
Qatar
Israel
Iran
Company Profiles
Depomed, Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Strategies
Janssen Pharmaceutical, Inc.
Grünenthal
Allergan, Plc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.